Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2020-02-13 4:05 pm Sale | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | VERTEX PHARMACEUTICALS INC VRTX | 2,690,470 4.4% | -2,690,470 (-50.00%) | View |
| 2020-02-12 09:27 am Purchase | 13G | VERTEX PHARMACEUTICALS INC VRTX | VANGUARD GROUP INC | 20,094,234 7.81% | 705,043 (+3.64%) | View |
| 2020-02-07 11:34 am Purchase | 13G | VERTEX PHARMACEUTICALS INC VRTX | FMR LLC | 24,282,962 9.443% | 3,334,948 (+15.92%) | View |
| 2020-02-06 09:10 am Purchase | 13G | VERTEX PHARMACEUTICALS INC VRTX | BlackRock Inc. BLK | 21,116,821 8.2% | 1,509,011 (+7.70%) | View |
| 2019-11-26 4:30 pm Unchanged | 13G | CRISPR THERAPEUTICS AG NAMEN A CRSP | VERTEX PHARMACEUTICALS INC VRTX | 5,380,940 9.1% | 0 (Unchanged) | View |
| 2019-06-07 4:04 pm Unchanged | 13D | CRISPR THERAPEUTICS AG NAMEN A CRSP | VERTEX PHARMACEUTICALS INC VRTX | 5,380,940 10.2% | 0 (Unchanged) | View |